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Abstract
Background:  The E-cadherin catenin system acts as an invasion suppressor of epithelial
malignancies. However, it is debatable whether expression of E-cadherin or catenins is a useful
prognostic marker in invasive breast cancer.
Methods: We measured the expression of E-cadherin and catenins (α-, β-, γ-catenin) in human
breast carcinomas using real time quantitative polymerase chain reaction (Q-PCR) and investigated
whether the expression levels were associated with known tumour variables or patient survival
(median follow-up 72.2 months). RNA from frozen sections of breast tissue (tumour n = 124,
background normal tissue n = 33) was reverse transcribed, quantified and analysed by Q-PCR with
results expressed as number of copies of transcript/50 ng RNA.
Results: There was no statistically significant difference in the expression of E-cadherin and
catenins (α-, β-, γ-catenin)in the 33 paired normal background and tumour tissues. The expression
of E-cadherin, α-, β-, and γ-catenin in node positive tumours was similar to node-negative tumours.
E-cadherin, α-, β-, and γ-catenin expression in breast tumours was not related to Nottingham
Prognostic Index (NPI). There was no significant difference in the expression of E-cadherin, α-, β-
, γ-catenin between the various TNM stages. None of the molecular markers significantly influenced
survival. Lymph node status was the only significant predictor of survival.
Conclusion: Using real time quantitative PCR there was no difference in the expression of E-
cadherin, α-, β-, γ-catenin between tumour and normal breast tissue. Furthermore, measurement
of expression of these molecules was not of prognostic value in predicting long term outcome of
women with breast cancer.
Background
Development of malignant tumours is in part character-
ized by the ability of a tumour cell to overcome cell-cell
adhesion and to invade surrounding tissue. The E-cad-
herin catenin complex localized to actin-based adherens
junctions plays a crucial role in epithelial cell-cell adhe-
sion and in the maintenance of tissue architecture. Pertur-
bation in the expression or function of this complex
results in loss of intercellular adhesion, with possible con-
sequent cell transformation and tumour progression.
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The main structure of E-cadherin catenin complex consists
of transmembrane E-cadherin, cytoplasmic proteins,
called catenins (α-, β- and γ-catenin), and actin cytoskele-
ton filament. β-catenin and γ-catenin share approximately
65% sequence homology and bind directly to the cyto-
plasmic tail of E-cadherin in a mutually exclusive manner.
α-catenin then links the bound β- or γ-catenin to the actin
microfilament network of the cytoskeleton[1,2].
In several carcinomas including gastric, head and neck,
bladder, prostate, colon, and breast, a reduced or absent
expression or abnormal location of E-cadherin has been
observed [3-8]. Studies on both cell lines and clinical
materials have provided evidence for the involvement of
E-cadherin in suppressing cancer progression[5,9-13].
However, there are conflicting reports as to the usefulness
of E-cadherin expression as an independent prognostic
marker in invasive breast cancer [14-20]. In general, reten-
tion of E-cadherin expression correlates with well-differ-
entiated, good prognosis and non-invasive
properties[21]. Junctional catenin expression is often lost
in cadherin-negative breast cancer and changes in catenin
phosphorylation may compromise adhesion in cadherin-
positive cancers[20,22-26]. However, few studies have
investigated simultaneously the expression of E-cadherin,
α-, β-, and γ-catenin. The expression of the various molec-
ular markers in previous studies has been assessed by
immunohistochemical staining in a small sample size.
The use of immunohistochemistry does present some
drawbacks in that staining interpretation may be some-
what subjective. It is also difficult to compare different
series with different cut-offs for positivity and negativity.
We determined the expression of E-cadherin, α-, β- and γ-
catenin in human breast carcinomas using real time quan-
titative polymerase chain reaction and investigated
whether the expression levels are associated with known
tumour variables or patient survival.
Methods
Patients and tumour specimens
Tumour tissue and normal background tissue (tissue away
from the primary tumour site and histologically con-
firmed to be free from cancer cells, from the same
patients) were collected with ethical approval and
informed consent from patients with invasive breast can-
cer. The fresh tumour and normal background tissues
were snap frozen in liquid nitrogen and stored at -70°C.
An overview of the clinical and pathological characteris-
tics is summarised in Table 1. Follow-up information was
obtained from the patient records at the hospital and the
median follow-up for patients still alive was 72.2 months
(at the time of these analyses). At the beginning of the
project, all the samples were re-visited histologically by a
consultant pathologist (ADJ, Department of Pathology,
Cardiff University) to confirm the histology, nature and
quality of tissues, as well as tumour/stroma ratio in each
tissue. These samples were subsequently used for immu-
nohistochemical staining and extraction of genetic mate-
rial.
Real time-quantitative polymerase chain reaction
The levels of E-cadherin, α-, β- and γ-catenin transcripts
from the prepared cDNA were determined by real time
quantitative RT-PCR, based on the Amplifluor™ technol-
ogy, using the method previously reported[27] Specific
primer pairs for E-cadherin, α-, β- and γ-catenin (Table 2)
were designed by the authors using a Beacon Designer
software (version 2, CA, USA) and manufactured by Invit-
rogen (Invitrogen Life Technologies, Paisley, Scotland,
UK). An additional sequence, known as the Z sequence
(5'actgaacctgaccgtaca'3 as underlined in Table 2), which is
complementary to the universal Z probe (Intergen Inc.,
England, UK) was added to one of the primer in the
primer pair. Each reaction included Hot-start Q-master
mix (Abgene), 10 pmol of specific forward primer, 1 pmol
of reverse primer (with the Z sequence), 10 pmol of FAM-
tagged probe (Intergen Inc.), and cDNA from approxi-
mate 50 ng RNA. An icyclerIQ™ (Bio-Rad) system,
Table 1: Clinicopathological characteristics
Variable n
Tissue type
Normal background 33
Tumour 124
Tumour grade
12 4
24 2
35 8
Histology
Invasive ductal 94
Invasive lobular 14
Other 16
Stage (TNM)
I7 0
II 40
III 7
IV 4
Unknown 3
NPIa
1 (good prognosis) 68
2 (moderate prognosis) 38
3 (poor prognosis) 16
Unknown 2
Outcome
Disease free 85
Metastatic disease 7
Local recurrence 5
Death (breast cancer related) 15
aNPI, Nottingham Prognostic IndexWorld Journal of Surgical Oncology 2008, 6:56 http://www.wjso.com/content/6/1/56
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equipped with an optical unit that allows real-time detec-
tion of 96 reactions was used to amplify the plasmid
standards and breast tissue samples under the following
conditions: 94°C for 12 minutes; 50 cycles of 94°C for 15
s, 55°C for 40 seconds and 72°C for 20 seconds. The puri-
fied plasmids served as internal standards and helped in
calculating the level of each tight junction molecule cDNA
(copies per 50 ng RNA) in the tissue samples. The prod-
ucts of Q-PCR were verified on agarose gels.
Antibodies
The primary antibodies used were monoclonal anti-E-cad-
herin (HECD-1, mouse IgG1 1:50, R&D systems, Oxon,
UK), anti-α-catenin (rabbit IgG1 1:50 dilution; Sigma),
anti-β-catenin (mouse IgG1 1:100, R&D systems, Oxon,
UK) and anti-γ-catenin (mouse IgG1 1:100, Sigma).
Immunohistochemical staining
Immunohistochemical staining was performed on 25
matched tumour and normal background tissue pairs.
Frozen sections of breast tumor and normal background
tissue were cut at a thickness of 6 μm using a cryostat. The
sections were mounted on Super Frost Plus microscope
slides, air-dried and then fixed in a mixture of 50% ace-
tone and 50% methanol. The sections were then placed in
'Optimax' (Vector Laboratories Ltd, Peterborough, UK)
wash buffer for 5–10 min to rehydrate. Sections were
incubated for 20 min in a 0.6% BSA blocking solution and
probed with the primary antibody. Following extensive
washings, sections were incubated for 30 min in the sec-
ondary biotinylated antibody (Multilink Swine anti-goat/
mouse/rabbit immunoglobulin; Dako Inc.). Following
washings, Avidin Biotin Complex (Vector Laboratories
Ltd) was then applied to the sections, followed by exten-
sive washings. Diaminobenzidine chromogen (Vector
Laboratories Ltd) was then added to the sections, which
were incubated in the dark for 5 minutes. Sections were
then counterstained in Mayer's haematoxylin and dehy-
drated in ascending grades of methanol before clearing in
xylene and mounting under a coverslip.
Quantitative image analysis of immunohistochemical 
stains
Image acquisition and processing
Slides were viewed using a 20 × 20 objective lens (Leitz,
DM IRB) and images were subsequently saved as a 24 bit
colour JPEG file image via a digital camera (Panasonic,
digital), and computer (Pentium III, RM machines, Mil-
ton Keynes UK) equipped with a frame grabber (Win TV,
Celebrity Edition from Hauppauge). The captured images
of tumour and normal background tissues were amalga-
mated using the PHOTOMERGE option in Adobe Pho-
toshop 6. The images were then converted into gray scale
images and inverted using Adobe Photoshop 6 before
analysing using Optimas image analysis software (Version
6, Optimas, UK).
The intensity was analysed using point morphometry. 10
representative points were marked on each image cap-
tured. Overall, optical intensity data (mean and SD) was
calculated by summing up the data from all images in the
two groups and subtracting the mean background read-
ing.
Statistical analysis
The data obtained was analysed using the MINITAB 13.32
(Minitab Inc. State College, PA, USA) programme. Statis-
tical significance was calculated using the two-sample stu-
dent t-test, non-parametric Mann-Whitney test and
ANOVA where appropriate. Multivariate analysis was
done for survival.
Results
The intensity of membrane staining for E-cadherin and all
catenin molecules was significantly more in normal back-
ground tissues compared with tumour tissues (mean ±
SD; E-cadherin normal background 169.6 ± 5.83, tumour
82.7 ± 12.78 p < 0.001; α-catenin normal background
163.22 ± 4.27, tumour 92.22 ± 21.02 p < 0.001, β-catenin
normal background 216.1 ± 15.94, tumour 99 ± 32.93 p
< 0.001, γ-catenin normal background 131.9 ± 24.99,
tumour 85.5 ± 29.93 p = 0.008).
In contrast, no statistically significant difference was seen
in the expression of E-cadherin, α-catenin, β-catenin and
γ-catenin in the 33 paired normal background and
tumour tissues (copies/50 ng RNA, mean ± SD: E-cad-
herin normal background 17.4 ± 3.8, tumour 16.5 ± 6.7 p
= 0.51; α-catenin normal background 13.5 ± 4.5, tumour
38.3 ± 30.3 p = 0.48, β-catenin normal background 0.048
± 0.029, tumour 0.057 ± 0.019 p = 0.68, γ-catenin normal
Table 2: Primer pairs used for real time quantitative-PCR 
analyses.
Primers for human α-catenin
ACATENINF1 caacccttgtaaacaccaat
ACATENINZR actgaacctgaccgtacaccttctccaagaaattctca
Primers for human β-catenin
BCATENINF8 agggattttctcagtccttc
BCATENINZF actgaacctgaccgtacacatgccctcatctaatgtct
Primers for human E-Cadherin
ECADF8 cagaaagttttccaccaaag
ECADZR actgaacctgaccgtacaaaatgtgagcaattctgctt
Primers for human γ-catenin
gCatF1 aacaagaacaaccccaagtt
gCatZr actgaacctgaccgtacatagttacgcatgatctgcacWorld Journal of Surgical Oncology 2008, 6:56 http://www.wjso.com/content/6/1/56
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background 1.255 ± 0.927, tumour 0.219 ± 0.157 p =
0.28).
The expression of E-cadherin, α-, β- and γ-catenin in node
positive tumours was similar to node-negative tumours
(copies/50 ng RNA, mean ± SD: E-cadherin node positive
35.5 ± 104.2, node negative 25.70 ± 35.13 p = 0.51; α-cat-
enin node positive 26.60 ± 61.79, node negative 17.25 ±
23.08 p = 0.84, β-catenin node positive 0.0973 ± 0.2003,
node negative 0.0895 ± 0.1686 p = 0.69, γ-catenin node
positive 0.635 ± 4.004 node negative 0.622 ± 1.948 p =
0.55).
There was no significant relationship of E-cadherin, α-cat-
enin, β-catenin and γ-catenin in breast tumours to Not-
tingham Prognostic Index (NPI) (E-cadherin p = 0.094, α-
catenin p = 0.144, β-catenin p = 0.378, γ-catenin p =
0.131).
There was a trend towards decreased E-cadherin expres-
sion in Grade 2 and 3 tumours compared to Grade 1
tumours but the differences were not statistically signifi-
cant. α-catenin expression was significantly increased in
Grade 2 tumours compared with Grade 1 tumours (p =
0.03). However, α-catenin expression in Grade 3 tumours
was similar to Grade 1 tumours. β-catenin expression was
similar in Grade 1 and 2 tumours. However, its expression
was significantly increased in Grade 3 tumours compared
to Grade 2 tumours (p = 0.054). γ-catenin expression was
similar in the 3 groups.
Surprisingly, there was no difference in the expression of
E-cadherin catenin complex between ductal and lobular
tumours.
The TNM Stages 3 and 4 were combined into a single
group for analyses as they were very small. There was no
significant difference in the expression of E-cadherin, α-,
β-, and γ-catenin between the various TNM stages (p =
0.282, p = 0.806, p = 0.838, p = 0.337 respectively).
E-cadherin expression in tumours of patients who were
disease free was significantly more compared to those
with metastatic disease, local recurrence or dying from
breast cancer (Disease free vs. poor outcome (metastatic
disease and/or local recurrence and/or death from breast
cancer) p = 0.012). There was no difference in α-catenin
and γ-catenin expression between the groups. β-catenin
expression was increased in patients dying from breast
cancer compared to disease free patients and the differ-
ence approached statistical significance (p = 0.052). Mul-
tivariate analysis was done using SPSS for mortality. None
of the molecular markers significantly influenced survival.
Lymph node status was the only significant predictor of
survival.
Discussion
In this study, we examined the expression of cell-cell
adhesion molecules E-cadherin, α-, β- and γ-catenin in
human breast cancer by quantitative real time polymerase
chain reaction. The mRNA levels of these markers were
related to clinicopathological variables and survival data.
The data from this study did not show any difference in
the expression of E-cahderin, α-, β- and γ-catenin between
tumour and related normal tissue. This contrasts with the
results of immunohistochemical staining in the present
study and most previously reported studies of E-cadherin
catenin complex in breast cancer, which have described
down-regulation of some of these molecules in tumouri-
genesis[20,23-26,28].
The disparity can be easily explained as this is the first
study to measure expression of the E-cadherin catenin
complex molecules by quantitative real time polymerase
chain reaction. Direct comparisons are not possible as
previous studies have varied widely in patient samples
and immunohistochemical scoring methods, which make
comparisons difficult.
It is possible that a defect in the E-cadherin catenin com-
plex without a change in its expression may be responsi-
ble for the malignant progression. Immunohistochemical
staining and Q-PCR reveal different information and each
has its advantages and disadvantages. Immunohisto-
chemical analysis provides vital information on the pro-
tein location in the cells, which is important when
studying cell adhesion molecules. However, the method
has obvious limitations in quantifying the true amount of
the protein in cells or tissues. Quantitative analysis of
mRNA as presented here has the unique advantage in pro-
viding quantitative information of the gene expression
concerned. However, this method does not provide infor-
mation about the location of the molecule within a cell
and may be considered 'over-sensitive'.
The expression of E-cadherin, α-, β- and γ-catenin was
similar in node positive and node negative tumours. Our
results suggest that expression of E-cadherin, α-, β- and γ-
catenin may persist into the later stages of breast carci-
noma. Siitonen et al. and Oka et al. found a correlation
between loss of E-cadherin and the presence of nodal
metastases[29,30], but this has not been widely reported.
Howard et al. recently reported increased E-cadherin
expression in tumour tissue with nodal metastases[14]. E-
cadherin expression is retained in inflammatory breast
cancer[31]. Furthermore, derivative metastases frequently
show strong E-cadherin expression[32]. One emerging
opinion is that dynamic, reversible modulation of E-cad-
herin catenin complex occurs during breast carcinoma
progression. E-cadherin catenin complex expression orWorld Journal of Surgical Oncology 2008, 6:56 http://www.wjso.com/content/6/1/56
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function is transiently reduced at the development stage
of primary tumours. This loss of adhesiveness at primary
site of tumours allows cancer cells to 'dissociate' from
each other. However, following invasion and degradation
of surrounding matrix, and migration into the vasculature
and surrounding tissue, E-cadherin catenin complex is re-
introduced and cells adhere to the vasculature and form
tumour emboli[14].
In contrast to most previous IHC studies [33-35], mRNA
expression of E-cadherin, α-, β- and γ-catenin was similar
in ductal and lobular tumours. This may be due to the fact
that quantitative analysis as given here reflects the total
amount of the molecule rather than in an individual cell
and that mRNA expression does not always correlate with
cellular protein expression. Moreover, most series
reported on membrane staining and did not include cyto-
plasmic staining as a separate category. Thus, it is possible
that lobular carcinoma cases with cytoplasmic staining
were included in the general category of reduced expres-
sion of E-cadherin staining.
E-cadherin expression was not associated with tumour
grade. Reduced E-cadherin expression has been associated
in the past with high histological grade[19,36]. Our
results suggest that this is not necessarily the case. Pre-
served or increased E-cadherin catenin expression sup-
ports the notion that it assists aggressive tumour growth
by providing a support structure for cells to adhere and
accelerates invasion and metastasis.
There are conflicting reports in the literature regarding the
relationship between E-cadherin catenin complex and
prognosis/survival. In this study, E-cadherin catenin com-
plex expression was not prognostic in breast cancer
patients or related to survival. Asgeirsson et al., and Hei-
mann et al., reported reduced expression of E-cadherin to
be associated with tumour recurrence, metastases, and
poor prognosis in breast cancer[15,16]. Not all studies
confirm these findings[14,19,37]. Other investigators
have shown that the abnormal expression of catenins is
related to poor prognosis or decreased sur-
vival[20,23,26,38].
Despite the apparent advantages of quantitation and sen-
sitivity, the use of quantitative real time polymerase chain
reaction does present some drawbacks. The technique is
highly sensitive and any contaminating cells (lym-
phocytes, stromal tissue) will lead to readings that belong
to non cancer cells. To overcome this problem, it is essen-
tial to isolate pure populations of tumour cells by micro
dissection.
Conclusion
In conclusion, using real time quantitative PCR we have
shown that there is no difference in the expression of E-
cahderin, α-, β- and γ-catenin between tumour and nor-
mal breast tissue. Furthermore, measurement of expres-
sion of these molecules is not of prognostic value in
predicting long term outcome of women with breast can-
cer.
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